Dr. James Dale, professor emeritus at the University of Tennessee, has been recognized for his decades-long work developing a vaccine against Group A streptococcus, the bacteria that causes rheumatic heart disease and claims nearly half a million lives each year. In honor of his efforts, the UT Research Foundation named him Innovator of the Year, UTHSC reported.
Dr. Dale expressed surprise at receiving the award, noting his admiration for younger innovators. His four-decade pursuit of a Group A streptococcus vaccine highlights a long-term commitment to a potential global health breakthrough. While a commercial license or widespread vaccine rollout has yet to materialize, Dale hopes his work inspires young scientists to approach their ideas with patience, persistence, and dedication.
Dr. Dale joined the University of Tennessee Health Sciences faculty in 1983 and has played a key role in combating infectious diseases. His work on streptococcus vaccines was partly motivated by the decline of the disease in wealthier nations after World War II, which reduced pharmaceutical industry interest, even as the disease continues to affect low- and middle-income countries. Todd Ponzio, vice president of the UT Research Foundation, praised Dale’s work as an example of translational science—addressing a clinical problem, developing a solution in the lab, and applying it to patient care.
Dr. Dale’s research has faced a gradual path, often waiting for scientific advances to align with his vision. His collaboration with Moderna has accelerated progress, allowing mRNA vaccines to be rapidly produced once the necessary amino acid sequences are identified—a process that previously took over a year. This approach could influence future vaccine development for rapidly evolving diseases such as influenza and COVID-19. Dr. Dale told UTHSC News that he believes mRNA vaccines represent the future, highlighting the practical potential of his work beyond academia.
In recent years, Dr. Dale’s work has drawn partnerships with Moderna and the Leducq Foundation. With UT Health Sciences achieving R1 status, placing it among the nation’s top research universities, Dale’s contributions have enhanced the university’s reputation while advancing potentially life-saving vaccine technology. He emphasizes that while the recognition is an honor, the focus remains on ongoing work, which continues daily with support from Moderna, which manufactures the vaccines, and the Leducq Foundation, which provides research funding.
